CN112426475A - 一种治疗淋巴细胞白血病的中药组合物 - Google Patents
一种治疗淋巴细胞白血病的中药组合物 Download PDFInfo
- Publication number
- CN112426475A CN112426475A CN202010821416.5A CN202010821416A CN112426475A CN 112426475 A CN112426475 A CN 112426475A CN 202010821416 A CN202010821416 A CN 202010821416A CN 112426475 A CN112426475 A CN 112426475A
- Authority
- CN
- China
- Prior art keywords
- parts
- lymphocytic leukemia
- traditional chinese
- chinese medicine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 208000028018 Lymphocytic leukaemia Diseases 0.000 title claims abstract description 31
- 208000003747 lymphoid leukemia Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims description 14
- 235000015162 Caesalpinia sappan Nutrition 0.000 claims abstract description 7
- 241000207925 Leonurus Species 0.000 claims abstract description 7
- 241001608711 Melo Species 0.000 claims abstract description 6
- 241000301400 Trogopterus Species 0.000 claims abstract description 6
- 210000003608 fece Anatomy 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 241000222684 Grifola Species 0.000 claims abstract description 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 4
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 4
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 3
- 241000209639 Biancaea sappan Species 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000207929 Scutellaria Species 0.000 claims description 2
- 230000009194 climbing Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 4
- 230000036737 immune function Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- 208000032839 leukemia Diseases 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 244000306301 Caesalpinia sappan Species 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 244000171085 Polyporus umbellatus Species 0.000 description 2
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000009235 Rubia cordifolia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗淋巴细胞白血病的中药，是由下列重量份的原料药组成：瓜蒂0.6～1.2重量份；吴茱萸1.5～3重量份；苏木、五灵脂、全福花、黄芩、重楼5～10重量份；猪苓、过山龙6～12重量份；狮子草9～18重量份。本发明可以增强机体免疫功能，杀死淋巴细胞白血病细胞、诱导淋巴细胞白血病细胞分化和凋亡、防止淋巴细胞白血病细胞转移，减轻患者痛苦、提高病人生存质量，提高了淋巴细胞白血病患者的治愈率，具有治疗效果显著、无毒副作用等特点。
Description
技术领域
本发明涉及中药的制备领域，特别是涉及一种治疗淋巴细胞白血病的中药组合物。
背景技术
淋巴细胞白血病累及周围血液、淋巴结及全身脏器。急性型常见于儿童，慢性型多见于中老。
传统治疗方法有种种缺陷，化疗药物几乎都是细胞毒性药物，在杀死肿瘤细胞的同时，对人体的正常细胞有一定的毒副作用，尤其是对分裂、增殖、比较快的细胞如骨髓造血细胞、胃肠道粘膜上皮细胞等。化疗会缩短患者生存时间且部分肿瘤对药物不敏感，化疗不可能彻底杀死体内所有淋巴细胞白血病细胞，在一定的时间内淋巴细胞白血病细胞还会复发或转移。
放射治疗常作为一种辅助治疗或姑息治疗手段。放射治疗在破坏肿瘤的同时，正常组织细胞也会受到一定的损害，超过这一限制剂量就会对组织产生不可逆损害，而且，放射治疗还可能降低机体的免疫力。
发明内容
本发明的目的在于改进已有技术的不足而提供一种治疗淋巴细胞白血病的中药组合物，使其可以有效的抵抗淋巴细胞白血病细胞、防止淋巴细胞白血病细胞转移，提高了淋巴细胞白血病患者的治愈率，具有治疗效果显著、无毒副作用等特点。
本发明提供了一种治疗淋巴细胞白血病的中药组合物，该中药组合物包括：本发明公开了一种治疗淋巴细胞白血病的中药，是由下列重量份的原料药组成：瓜蒂0.6～1.2重量份；吴茱萸1.5～3重量份；苏木、五灵脂、全福花、黄芩、重楼5～10重量份；猪苓、过山龙6～12重量份；狮子草9～18重量份。
在一个优选的实施方案中，所述治疗淋巴细胞白血病的中药组合物由下列重量份的原料药组成：瓜蒂1.2重量份；吴茱萸3重量份；苏木、五灵脂、全福花、黄芩、重楼10重量份；猪苓、过山龙12重量份；狮子草18重量份。
本发明还提供一种治疗淋巴细胞白血病的口服制剂，该口服制剂由上述中药组合物制成。
其中，五灵脂味苦；甘；性温归经肝；脾经活血止痛；化瘀止血；消积解毒。孕妇慎服。五灵脂对淋巴白血病的细有显著的细胞毒性。
瓜蒂：苦，寒。有毒。催吐，退黄疸。瓜蒂对体外培养的慢性淋巴白血病的细胞有较强的细胞毒作用，其效力是正常淋巴细胞的5倍。
吴茱萸：辛、苦，热；有小毒。归肝、脾、胃、肾经。散寒止痛，降逆止呕，助阳止泻。吴茱萸果实的提取物对淋巴细胞白血病细胞的细胞有的细胞毒性。
全福花：咸，温。入肺、肝、胃经。消痰，下气，软坚，行水。全福花对淋巴细胞白血病细胞有毒性。
黄芩：苦，寒。归肺、胆、脾、大肠、小肠经。清热燥湿，泻火解毒，止血，安胎。黄芩对淋巴细胞白血病的细胞有细胞毒作用。
猪苓：甘、淡，平。归肾、膀胱经。利水渗湿。猪苓对淋巴细胞白血病的扩散有细胞毒性。
重楼：苦，微寒；有小毒。归肝经。清热解毒，消肿止痛，凉肝定惊。重楼对淋巴细胞白血病有显著抑制作用。
过山龙： 苦，寒。归肝经。凉血，止血，祛瘀，通经。对淋巴细胞白血病有显着疗效。茜草的粗提取物还有促进小鼠骨髓造血干细胞增殖和分化，升高白细胞作用。
狮子草：苦、辛，寒。清热，解毒，消肿。狮子草水煎液对急性淋巴细胞型白血病患者的血细胞脱氢酶都有较强的抑制作用；对于该类白血病患者白细胞的呼吸也有明显抑制作用。
苏木：甘、咸，平。归心、肝、脾经。行血祛瘀，消肿止痛。苏木水对人淋巴细胞血病的细胞有明显的杀伤作用，能明显延长患者的生存时间。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以某些成分确定、功效明晰的天然提取物的有序配伍，组合成了有诱导淋巴细胞白血病细胞凋亡与促使其分化的中药。
本发明既有化学治疗之功，又平和无毒，可谓“零毒化疗”。 用药多年来，患者无任何不良反应，跟踪血液检查正常，且疗效不反弹。在二十例晚期淋巴细胞白血病的纯中医治疗中，治愈率50%，5年以上生存率45%，有效率100%。
本发明可以使各中药成分在发挥其抗癌作用的同时相互协同，相辅相成，可以起到相互促进的作用，既能抑制淋巴细胞白血病细胞的增值，又能杀死淋巴细胞白血病细胞诱导淋巴细胞白血病细胞凋亡，起到治疗淋巴细胞白血病的作用，快速帮助患者康复。
本发明能够帮助晚期淋巴细胞白血病患者改善症状、减轻痛苦、提高病人生存质量。对于已复发或转移及无法进行放化疗治疗的患者，通过单独服用本配方中药，增强机体免疫功能，诱导淋巴细胞白血病细胞分化和凋亡，也可以达到延长病人生命的作用，长期生存，甚至有可能治愈。
本发明所述的中药组合物可用于治疗淋巴细胞白血病，具有显著疗效。本发明治疗费用相对低廉，远远低于西医的治疗费用。
本发明的中药组合物原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明还提供了一种由上述治疗该病的中药组合物制成的口服制剂，所述口服制剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为口服液和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗淋巴细胞白血病的中药，其特征是由下列重量份的原料药组成：瓜蒂0.6～1.2重量份；吴茱萸1.5～3重量份；苏木、五灵脂、全福花、黄芩、重楼5～10重量份；猪苓、过山龙6～12重量份；狮子草9～18重量份。
2.根据权利要求1所述的一种治疗淋巴细胞白血病的中药，其特征是由下列重量份的原料药组成：瓜蒂1.2重量份；吴茱萸3重量份；苏木、五灵脂、全福花、黄芩、重楼10重量份；猪苓、过山龙12重量份；狮子草18重量份。
3.一种治疗淋巴细胞白血病的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗淋巴细胞白血病的口服制剂，其特征是，所述口服制剂包括口服液、片剂、胶囊剂、丸剂，优选口服液和片剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010821416.5A CN112426475A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗淋巴细胞白血病的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010821416.5A CN112426475A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗淋巴细胞白血病的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112426475A true CN112426475A (zh) | 2021-03-02 |
Family
ID=74690356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010821416.5A Pending CN112426475A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗淋巴细胞白血病的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426475A (zh) |
-
2020
- 2020-08-15 CN CN202010821416.5A patent/CN112426475A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066445A (zh) | 一种根治胃病的中药制剂 | |
| CN104324125A (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
| CN113304226A (zh) | 一种治疗肺癌的中药组合物 | |
| CN113368205A (zh) | 一种治疗胃癌的中药组合物 | |
| CN112426475A (zh) | 一种治疗淋巴细胞白血病的中药组合物 | |
| CN104825817B (zh) | 一种具有抗肿瘤作用的中药制剂 | |
| CN105396017A (zh) | 一种治疗脂肪肝的中药制剂及其制备方法 | |
| CN104548033A (zh) | 一种治疗肠炎的铁苋菜中药制剂及其制备方法 | |
| CN107174603A (zh) | 一种延缓衰老的中药 | |
| CN112426491A (zh) | 一种治疗恶性黑色素瘤的中药组合物 | |
| CN112426486A (zh) | 一种治疗早幼粒细胞白血病的中药组合物 | |
| CN106938031A (zh) | 一种甲状腺瘤的治疗药物 | |
| CN112426500A (zh) | 一种治疗宫颈癌的中药组合物 | |
| CN112426469A (zh) | 一种治疗艾氏腹水癌的中药组合物 | |
| CN112316071A (zh) | 一种治疗肝癌的中药组合物 | |
| CN112245518A (zh) | 一种治疗粒细胞型白血病的中药组合物 | |
| CN112426478A (zh) | 一种治疗肠癌的中药组合物 | |
| CN111714601A (zh) | 一种治疗真菌感染的中药组合物 | |
| CN101028352A (zh) | 一种治疗坐骨神经痛的中药制剂 | |
| CN105125855A (zh) | 一种配合肿瘤化疗的中药组合物 | |
| CN112426465A (zh) | 一种治疗鼻咽癌、鳞状细胞癌的中药组合物 | |
| CN113648391A (zh) | 一种治疗白血病的中药组合物 | |
| CN104840921A (zh) | 一种治疗肠炎的薏苡仁制剂及其制备方法 | |
| CN111905078A (zh) | 一种主治痛风病的药物 | |
| CN111759946A (zh) | 一种治疗疝气的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210302 |